Overview
Established 5 years ago, our bulk drugs intermediate formulation unit in Mohali is now available for sale. The facility is situated on 2 acres of land with a built-up area of 40,400 sq ft. Our installed capacity is 190 KL/reactors, but we are currently operating at 10% production capacity. Our API product list includes Aceclofenac IP, Ascorbic Acid IP, Clarithromycin, Diclofenac IP, 2 Ethyl Sodium Hexonate, Pantoprazole IP, and Sodium Citrate IP, among others. Our intermediates include Calcium Phosphoryl, Choline Chloride (CPCC, intermediate of Citicoline Sodium), OPA (Ortho Phenoxy Aniline), and OPMSA (Ortho Phenoxy Methane Sulfonilide), among others. We are dedicated to providing high-quality, cost-effective products and have established a portfolio of affordable medicines accessible to all. This is an excellent opportunity for investors looking to acquire a well-equipped pharmaceutical manufacturing unit with significant growth potential.
Owned Pharmaceutical Industry API Bulk Drugs
Business Details
2020
Year of Establishment
55
No. of Employees
Running
Current Status of Business
NoBusiness Relocatable
OwnedProperty Type
N.A Property Value
N.A Property Classification
Describe Property
N.A
Competition / Market
Yes we have some competition
Products & Services
Our API product list includes Aceclofenac IP, Ascorbic Acid IP, Clarithromycin, Diclofenac IP, 2 Ethyl Sodium Hexonate, Pantoprazole IP, and Sodium Citrate IP, among others. Our intermediates include Calcium Phosphoryl, Choline Chloride (CPCC, intermediate of Citicoline Sodium), OPA (Ortho Phenoxy Aniline), and OPMSA (Ortho Phenoxy Methane Sulfonilide)
Growth Potential
Growth rate is high
Reason For Sale
Working capital shortage
Financial Details
EBITDA :-
N.A
PAT :-
N.A
Debt :-
N.A
How the Acquisition Process Works
- 01Contact SellerContact Seller
- 02Teaser/Information MemorandumTeaser/Information Memorandum
- 03Valuation ReportValuation Report
- 04FinancialsFinancials
- 05Schedule an Advisory MeetingBook Your Consultation